SHR-1703
Phase 3Small molecule
Guangdong Hengrui Pharmaceutical Co., LtdSHR-1703 is one of 35 small molecule programs targeting Granulomatosis with Polyangiitis. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
161 competitors in Asthma
#DrugCompanyPhaseTrials
1SHR-1703
Guangdong Hengrui Pharmaceutical Co., LtdPhase 3
Celexa
AbbViePreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
DUPIXENT
RegeneronPreclinical
Atrovent
Boehringer IngelheimPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ozone
TTanta University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma3 trials
Granulomatosis with Polyangiitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1703. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details